Investigating T cell changes in patients experiencing side effects from cancer immunotherapy
Single-cell dissection of CD4 T cell changes in patients with immune-related adverse events following PD-1 inhibition
['FUNDING_CAREER'] · UNIVERSITY OF PENNSYLVANIA · NIH-11012869
This study is looking at how a type of cancer treatment called PD-1 therapy can sometimes cause side effects related to the immune system, and it will compare patients who have these side effects with those who don’t to better understand why they happen and how vaccinations might help identify any hidden immune problems.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11012869 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how PD-1 checkpoint inhibition, a type of cancer immunotherapy, can lead to immune-related adverse events (irAEs) in patients. The study will analyze two groups of patients: one group receiving PD-1 therapy who develop irAEs and another group who do not. By examining the differences in CD4 T cell behavior and characteristics between these groups, the research aims to uncover the mechanisms that trigger these adverse effects. Additionally, the study will explore how vaccination may reveal underlying immune issues in patients experiencing irAEs.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients receiving PD-1 immunotherapy who may experience immune-related adverse events.
Not a fit: Patients not undergoing PD-1 immunotherapy or those who do not experience immune-related adverse events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management and prevention of immune-related side effects in patients undergoing PD-1 immunotherapy.
How similar studies have performed: Previous research has shown promising results in understanding immune responses related to PD-1 inhibition, indicating that this approach may yield valuable insights.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: APOSTOLIDIS, SOKRATIS — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: APOSTOLIDIS, SOKRATIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy